Evropska unija - slovenščina - EMA (European Medicines Agency)

medimmune llc - reassortant virus influence (v živo zmanjšan) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 kot seva a/victoria/361/2011 (h3n2), kot sev b/italija/2/2012 kot sev - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih od 24 mesecev do manj kot 18 let. uporaba fluenz, ki mora temeljiti na uradnih priporočilih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - reasortantni virus gripe (živi oslabljen) s sevom: a / vietnam / 1203/2004 (h5n1) - gripa, človek - cepiva - preprečevanje gripe pri uradno prijavljeni pandemični situaciji pri otrocih in mladostnikih od 12. meseca do starosti manj kot 18 let. pandemije gripe cepiva proti h5n1 astrazeneca je treba uporabljati v skladu z uradnimi smernice.

Evropska unija - slovenščina - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - amlodipin; atorvastatin; perindopril - filmsko obložena tableta - amlodipin 5 mg / 1 tableta  atorvastatin10 mg / 1 tableta  perindopril3,4 mg / 1 tableta; atorvastatin 10 mg / 1 tableta  perindopril3,4 mg / 1 tableta; perindopril 3,4 mg / 1 tableta - atorvastatin, amlodipin in perindopril

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - amlodipin; atorvastatin; perindopril - filmsko obložena tableta - amlodipin 10 mg / 1 tableta  atorvastatin20 mg / 1 tableta  perindopril6,79 mg / 1 tableta; atorvastatin 20 mg / 1 tableta  perindopril6,79 mg / 1 tableta; perindopril 6,79 mg / 1 tableta - atorvastatin, amlodipin in perindopril

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - amlodipin; atorvastatin; perindopril - filmsko obložena tableta - amlodipin 5 mg / 1 tableta  atorvastatin20 mg / 1 tableta  perindopril6,79 mg / 1 tableta; atorvastatin 20 mg / 1 tableta  perindopril6,79 mg / 1 tableta; perindopril 6,79 mg / 1 tableta - atorvastatin, amlodipin in perindopril

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - amlodipin; atorvastatin; perindopril - filmsko obložena tableta - amlodipin 5 mg / 1 tableta  atorvastatin20 mg / 1 tableta  perindopril3,4 mg / 1 tableta; atorvastatin 20 mg / 1 tableta  perindopril3,4 mg / 1 tableta; perindopril 3,4 mg / 1 tableta - atorvastatin, amlodipin in perindopril

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - amlodipin; atorvastatin; perindopril - filmsko obložena tableta - amlodipin 10 mg / 1 tableta  atorvastatin40 mg / 1 tableta  perindopril6,79 mg / 1 tableta; atorvastatin 40 mg / 1 tableta  perindopril6,79 mg / 1 tableta; perindopril 6,79 mg / 1 tableta - atorvastatin, amlodipin in perindopril

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.